Loading…
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $90M | $-49M | $-54M | $-33M | -99.8% | 8.0% | -4.2% |
| 2024 | $84M | $-51M | $-56M | $-33M | -65.7% | 22.0% | -7.3% |
| 2023 | $69M | $-55M | $-61M | $-38M | -51.4% | 28.0% | 3.3% |
| 2022 | $54M | $-56M | $-59M | $-46M | -38.3% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 53.66 | 68.68 | 83.79 | 90.50 |
| Operating Revenue | - | 53.66 | 68.68 | 83.79 | 90.50 |
| Cost Of Revenue | - | 13.80 | 17.92 | 21.79 | 23.36 |
| Gross Profit | - | 39.86 | 50.75 | 62 | 67.14 |
| Operating Expense | - | 98.50 | 112.69 | 119.70 | 120.80 |
| Research And Development | - | 15.40 | 18.08 | 17.57 | 19.49 |
| Selling General And Administration | - | 83.10 | 94.61 | 102.14 | 101.31 |
| Total Expenses | - | 112.30 | 130.61 | 141.49 | 144.16 |
| Operating Income | - | -58.64 | -61.94 | -57.70 | -53.66 |
| Total Operating Income As Reported | - | -58.64 | -61.94 | -57.70 | -53.66 |
| EBITDA | - | -55.99 | -55.49 | -50.89 | -49.17 |
| Normalized EBITDA | - | -55.99 | -55.49 | -50.89 | -49.17 |
| EBIT | - | -57.50 | -57.04 | -52.39 | -50.22 |
| Interest Income | - | 1.53 | 5.57 | 5.06 | 2.65 |
| Interest Expense | - | 1.07 | 3.23 | 3.51 | 3.16 |
| Net Interest Income | - | 0.46 | 2.34 | 1.55 | -0.50 |
| Other Non Operating Income Expenses | - | -0.40 | -0.67 | 0.26 | 0.79 |
| Other Income Expense | - | -0.40 | -0.67 | 0.26 | 0.79 |
| Interest Income Non Operating | - | 1.53 | 5.57 | 5.06 | 2.65 |
| Interest Expense Non Operating | - | 1.07 | 3.23 | 3.51 | 3.16 |
| Net Non Operating Interest Income Expense | - | 0.46 | 2.34 | 1.55 | -0.50 |
| Pretax Income | - | -58.57 | -60.27 | -55.89 | -53.38 |
| Tax Provision | - | 0.35 | 0.57 | 0.50 | 0.63 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -58.92 | -60.84 | -56.39 | -54 |
| Net Income From Continuing And Discontinued Operation | - | -58.92 | -60.84 | -56.39 | -54 |
| Net Income From Continuing Operation Net Minority Interest | - | -58.92 | -60.84 | -56.39 | -54 |
| Net Income | - | -58.92 | -60.84 | -56.39 | -54 |
| Net Income Common Stockholders | - | -58.92 | -60.84 | -56.39 | -54 |
| Net Income Including Noncontrolling Interests | - | -58.92 | -60.84 | -56.39 | -54 |
| Normalized Income | - | -58.92 | -60.84 | -56.39 | -54 |
| Diluted NI Availto Com Stockholders | - | -58.92 | -60.84 | -56.39 | -54 |
| Basic Average Shares | - | 37.10 | 37.97 | 39.11 | 40.69 |
| Diluted Average Shares | - | 37.10 | 37.97 | 39.11 | 40.69 |
| Reconciled Depreciation | - | 1.51 | 1.55 | 1.49 | 1.05 |
| Reconciled Cost Of Revenue | - | 13.80 | 17.92 | 21.79 | 23.36 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Pulmonx Corporationthis co. | LUNG | $68M | - | 1.26 | -99.8% | - |
| Outset Medical, Inc. | OM | $88M | -1.07 | 0.69 | -64.3% | -2.46 |
| Aardvark Therapeutics, Inc. | AARD | $86M | -1.49 | 0.81 | -54.0% | -0.63 |
| biote Corp. | BTMD | $84M | 3.10 | -1.43 | -46.2% | 3.25 |
| LENSAR, Inc. | LNSR | $68M | -1.98 | -2.61 |
| - |
| - |
| - |
| - |
| - |
| 131.7% |
| -2.88 |
| DocGo Inc. | DCGO | $56M | -0.31 | 0.39 | -126.7% | -0.47 |
| aTyr Pharma, Inc. | ATYR | $50M | -0.68 | 0.75 | -109.8% | -0.68 |
| Myomo, Inc. | MYO | $50M | -3.20 | 4.37 | -136.6% | -4.36 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $46M | -2.09 | 5.86 | -280.5% | - |
| Peer Median | - | -1.28 | 0.72 | -87.1% | -0.68 | |